🇺🇸 FDA

Intelligence Platform

Patents

Browse 1,015 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 9598432

2,4-pyrimidinediamine compounds and uses as anti-proliferative agents

Rigel Pharmaceuticals, Inc. · Granted Tue Mar 21 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 16 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9592238

Anti-ceramide monoclonal antibody 2A2

The Board of Regents of the University of Texas System · Granted Tue Mar 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9580472

Anti-microbial peptides and methods of use thereof

BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Tue Feb 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9572873

Method of inducing a T lymphocyte response using T-cell immunogens derived from anti-viral

The Regents of the University of California · Granted Tue Feb 21 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 16 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9554587

Anti-regurgitation composition maintaining gut motility

UNITED PHARMACEUTICALS · Granted Tue Jan 31 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 26 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9556232

Anti-angiogenic molecules, nanostructures and uses thereof

Northwestern University · Granted Tue Jan 31 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 26 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9550837

Therapeutic uses of anti-PCSK9 antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 24 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 19 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9546370

QSOX1 as an anti-neoplastic drug target

ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Tue Jan 17 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 12 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9546218

Anti-Tie2 antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 17 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 12 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9545451

Anti-PRLR antibodies and methods for killing PRLR-expressing cells

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 17 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 12 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9545461

Anti-microbial peptides and methods of use thereof

The Regents of the University of California · Granted Tue Jan 17 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 12 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9540449

Anti-PCSK9 antibodies with pH-dependent binding characteristics

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 10 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 05 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9534033

Targeted interferons demonstrating potent apoptotic and anti-tumor activities

The Regents of the University of California · Granted Tue Jan 03 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 29 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9533039

Methods of treating systemic lupus erythematosus (SLE) using anti-CD48 antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 03 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 29 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9527919

High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and d

The Regents of the University of California · Granted Tue Dec 27 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 22 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9527917

Nucleic acid encoding anti-OX40 antibodies

The Board of Regents of the University of Texas System · Granted Tue Dec 27 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 22 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9522955

Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of s

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Dec 20 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 15 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9517243

Beta-mannosylceramide and stimulation of NKT cell anti-tumor immunity

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Dec 13 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 08 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9512125

Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents

The Regents of the University of California · Granted Tue Dec 06 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 01 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9506926

Molecular predictors of therapeutic response to specific anti-cancer agents

The Regents of the University of California · Granted Tue Nov 29 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 24 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9499554

Anti-influenza compositions and methods

BioCryst Pharmaceuticals, Inc. · Granted Tue Nov 22 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 17 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9487573

Murine anti-NY-ESO-1 T cell receptors

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Nov 08 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 03 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9475880

Anti-CD134 (OX40) antibodies and uses thereof

Biocerox Products B.V. · Granted Tue Oct 25 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 20 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9475875

Anti-EGFRvIII antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 25 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 20 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted